semaglutide news today october 2025 Compound versions of GLP-1 drugs for weight loss halted by FDA Novo cuts GLP-1 prices 70%,

Weight loss achieved with standard doses of GLP-1 agonists (GLP-1a) among real-world patients with type 2 diabetes has not been determined

Alexandra Sowa discusses the surge in GLP-1 use, concerns over prescriptions without in-person visits and how ChatGPT health may help patients get faster treatment.

Common nutritional concerns associated with GLP-1 therapy may include: Reduced appetite and inadequate nutrient intake Loss of lean muscle mass during rapid weight reduction Nausea, digestive discomfort, and poor food tolerance Fatigue and reduced energy levels Micronutrient deficiencies over long-term use Increased nutritional needs in patients with complex clinical conditions Effective GLP-1 treatment requires more than medication alone

Health Canada is warning people not to buy or use fake or unauthorized versions of GLP-1 drugs such as semaglutide, the active ingredient in Ozempic and Wegovy